Use of statins in the treatment of ischemic diseases

Abstract

The invention discloses statins compounds used as local intraosseous application for the treatment of ischemic diseases, in particular, discloses local intraosseous application of statin compounds in the treatment of peripheral ischemic diseases or cardio-cerebrovascular ischemic diseases.

We claim: 
     
       1. A method of treating ischemic disease in a subject in need thereof comprising intraosseously administering to the subject in need thereof a composition comprising 0.1 mg to 50 mg of a statin or a pharmaceutically acceptable salt thereof, wherein said composition is administered by a single injection, and wherein the composition is administered once every 7 to 600 days. 
     
     
       2. The method of  claim 1 , wherein the statin is selected from the group consisting of simvastatin, atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, pitavastatin, bervastatin, cerivastatin, crilvastatin, dalvastatin, mevasatin, tenivastatin and any combinations thereof. 
     
     
       3. The method of  claim 1 , wherein the statin is simvastatin. 
     
     
       4. The method of  claim 1 , wherein said composition further comprises a pharmaceutically acceptable carrier. 
     
     
       5. The method of  claim 1 , wherein said pharmaceutically acceptable salt of the statin is selected from the group consisting of hydrochloride, hydrobromide, hydriodate, sulfate, nitrate, phosphate, citrate, mesylate, trifluoroacetate, and acetate. 
     
     
       6. The method of  claim 1 , wherein the composition is administered once every 10 to 500 days. 
     
     
       7. The method of  claim 1 , wherein the composition is administered once every 30 to 300 days. 
     
     
       8. The method of  claim 1 , wherein the dose of the statin or pharmaceutically acceptable salt thereof ranges from 0.5 mg to 10 mg. 
     
     
       9. The method of  claim 1 , wherein said ischemic disease is peripheral ischemic disease. 
     
     
       10. The method of  claim 1 , wherein said ischemic disease is diabetic acromelic ischemic disease. 
     
     
       11. The method of  claim 1 , wherein the composition is administered once every 30 to 600 days. 
     
     
       12. The method of  claim 1 , wherein said ischemic disease is cardio-cerebrovascular ischemic disease.